Sirnaomics Out-Licenses siRNA Influenza Vaccine Candidate to Walvax

Sirnaomics Biopharma ( Suzhou ) out-licensed Greater China rights for its anti-influenza siRNA therapeutic candidate to Walvax Biotech, a Kunming vaccine company. Walvax made a $6.4 million upfront payment and will also be responsible for undisclosed milestone and royalty payments. To develop STP702, Sirnaomics identified potent siRNA sequences that target highly conserved regions of influenza viral genes, a combination that exhibited broad anti-influenza activity. The nanoparticle-enhanced siRNA delivery also improves the candidate's anti-influenza activity, which is higher than marketed flu products, the company said. More details.... Share this with colleagues: // //